key: cord-0927937-df5vivw6
authors: Mageau, Arthur; Papo, Thomas; Ruckly, Stephane; Strukov, Andrey; van Gysel, Damien; Sacre, Karim; Timsit, Jean-François
title: Survival after COVID-19-associated organ failure among inpatients with systemic lupus erythematosus in France: a nationwide study
date: 2021-12-09
journal: Ann Rheum Dis
DOI: 10.1136/annrheumdis-2021-221599
sha: 0a4f43941cfa5cd02179b0b5335187619c460782
doc_id: 927937
cord_uid: df5vivw6

OBJECTIVE: We analysed the incidence of, the specific outcomes and factors associated with COVID-19-associated organ failure (AOF) in patients with systemic lupus erythematosus (SLE) in France. METHODS: We performed a cohort study using the French national medical/administrative hospital database for the January 2011–November 2020 period. Each patient with SLE diagnosed in a French hospital with a COVID-19-AOF until November 2020 was randomly matched with five non-SLE patients with COVID-19-AOF. We performed an exact matching procedure taking age ±2 years, gender and comorbidities as matching variables. COVID-19-AOF was defined as the combination of at least one code of COVID-19 diagnosis with one code referring to an organ failure diagnosis. RESULTS: From March to November 2020, 127 380 hospital stays in France matched the definition of COVID-19-AOF, out of which 196 corresponded with patients diagnosed with SLE. Based on the presence of comorbidities, we matched 908 non-SLE patients with COVID-19-AOF with 190 SLE patients with COVID-19-AOF. On day 30, 43 in-hospital deaths (22.6%) occurred in SLE patients with COVID-19-AOF vs 198 (21.8%) in matched non-SLE patients with COVID-19-AOF: HR 0.98 (0.71–1.34). Seventy-five patients in the SLE COVID-19-AOF group and 299 in the matched control group were followed up from day 30 to day 90. During this period, 19 in-hospital deaths occurred in the SLE group (25.3%) vs 46 (15.4%) in the matched control group; the HR associated with death occurring after COVID-19-AOF among patients with SLE was 1.83 (1.05–3.20). CONCLUSIONS: COVID-19-AOF is associated with a poor late-onset prognosis among patients with SLE.

The interplay between COVID-19 and systemic lupus erythematosus (SLE) has yet to be defined. Indeed, many patients with SLE are exposed to immunosuppressive drugs, are more susceptible to viral infections and often suffer from chronic kidney or cardiovascular diseases, which are additional risk factors for severe COVID-19. 1 On the other hand, glucocorticoids and hydroxychloroquine, the drugs most widely used in SLE treatment, have also been investigated to treat COVID-19. 2 3 Moreover, type 1 interferon (IFN) such as IFNα and the antibodies anti-IFNα are involved both in SLE and severe COVID-19. [4] [5] [6] [7] Although currently available data regarding the impact of COVID-19 in SLE sound reassuring, [8] [9] [10] [11] most studies are based on a small number of patients. Finally, comparison between SLE, which mainly affects women of childbearing age, and the general population with regard to severe COVID-19 may be challenging.

We used a French nationwide medical and administrative database to analyse the incidence, the specific outcomes and the characteristics associated with COVID-19-associated organ failure (COVID-19-AOF) in patients with SLE.

Data of all patients admitted to French hospitals from January 2011 to November 2020 with at least one diagnosis of infection associated with an organ failure and/or SLE were collected from the national medical administrative database, the PMSI (Programme de Médicalisation des Systèmes d'Informations, Information System Medicalization Program). The PMSI database provides a summary with diagnosis and individual medical conditions at discharge of any public or private French healthcare

What is already known about this subject? ► The interplay between COVID- 19 

We defined COVID-19-AOF as the combination of at least one of the diagnosis codes of COVID-19 (ICD-10 codes 'U071', 'U0710', 'U0711', 'U0712', 'U0714', 'U0715'), with one code referring to an organ failure diagnosis (listed in online supplemental materials). This definition, which matches the definition for sepsis, has been previously used and validated in medical administrative database studies. [12] [13] [14] To be allocated in the SLE group, COVID-19-AOF had to follow or be concomitant with an SLE 'M32' code. For an exhaustive description of diagnosis and procedure codes used, see online supplemental materials.

To determine patients' phenotype, we used all the specific diagnostic codes reported during or before the COVID-19-AOF stay.

Each patient with SLE who experienced COVID-19-AOF during the period of study was randomly matched with five non-SLE control patients with COVID-19-AOF and one patient with SLE without evidence of COVID-19 infection. We used a random exact matching procedure (without replacement) using the following matching variables: age ±2 years, gender, chronic kidney disease, arterial hypertension, cardiovascular history, diabetes mellitus, chronic pulmonary disease and obesity. We verified matching accuracy and efficacy by calculating the standardised differences for the matching variables between the various matched populations.

Kaplan-Meier method was used to present 90-day survival, taking day 0 as the first hospital admission for COVID-19-AOF. For the control SLE non-COVID-19 population, we used the first day of a randomly selected stay before 2020 (2011-2020 period) as day 0. In order to calculate the HR of death after COVID-19-AOF according to SLE status, and because we cannot assume the proportional hazard hypothesis for the whole period between day 0 (D0) and day 90 (D90), we split this period into two parts: D0-D30 and D30-D90. For the second time period, we considered only the subgroups of patients who survived after 30 days of follow-up, taking D30 as the new day 0. We used standard univariable Cox proportional hazard model for the unmatched analysis and univariable marginal Cox proportional hazard model 15 for the postmatching analysis.

Categorical variables are presented as number (percentage). Quantitative variables are presented as median (first quartile-third quartile). HRs are presented with their 95% CI. We used Student's t-test and χ 2 test for univariable comparisons, as appropriate. All analyses were performed using SAS V.9.4 software. Kaplan-Meier curves were built with R V.4.0.3 software.

From March to November 2020, 127 380 hospital stays in France matched the definition of COVID-19-AOF. Among them, there were 196 unique patients with SLE and 113 567 unique patients without SLE. A flow chart of these selected populations is presented in online supplemental figure S1. A comparison of SLE patients with COVID-19-AOF versus non-SLE patients with COVID-19-AOF is presented in table 1. The characteristics of patients with SLE admitted to hospital within the study period but without any evidence of COVID-19 are also presented for information. Briefly, SLE patients with COVID-19-AOF were younger (65 (52-76) years vs 76 (64-86) years; p<0.0001), less frequently male (n=50 (25.5%) vs n=56 601 (57.8%); p<0.0001) and had more comorbidities than the general population with COVID-19-AOF. Patients with SLE were also more frequently admitted to the intensive care unit (ICU) (n=83 (42.4%) vs n=40 304 (35.6%); p=0.04) and underwent more often renal replacement therapy for acute kidney injury (AKI; n=14 (7.1%) vs n=3744 (3.3%); p=0.003).

At D30, 43 (21.9%) in-hospital deaths occurred among SLE patients with COVID-19-AOF vs 31 274 (27.6 %) in the unmatched non-SLE patients with COVID-19-AOF. In the D0-D30 period, the HR of death associated with presence of SLE was 0.69 (0.51-0.93). At D90, there was no perceptible difference regarding in-hospital mortality between both groups: 59 deaths (30.1%) in the SLE group vs 35 130 (30.9%) in the control group. In the D30-D90 period, the HR of death associated with presence of SLE was 1.52 (0.93-2.47). A sensitivity analysis using Cox model adjusted for age and sex is presented in online supplemental figure S6.

The Kaplan-Meier curve of the 90-day survival of these populations is displayed in figure 1 . The survival of an unmatched SLE population without any evidence of COVID-19 is also displayed for information.

Based on the presence of comorbidities, we were able to match 908 non-SLE patients with COVID-19-AOF and 170 SLE patients without COVID-19 with 190 SLE patients with COVID-19-AOF.

The characteristics of these matched populations as well as the standardised differences for the matching variables are displayed in table 2. The rate of ICU admission was similar between patients with SLE and matched patients without SLE 05-3.20) . A sensitivity analysis using a rematch procedure for patients still alive at D30 is presented in online supplemental figure S7-S8.

All HRs calculated for the crude and the matched analyses are summarised in table 3.

Analysis of healthcare use post COVID-19-AOF for the matched population still alive at D30 is presented in online supplemental figure S5. We observed that patients with SLE had more reports of coinfection diagnoses than the matched control patients (mean (±SD): 9.09 (±8.5) in the SLE group vs 7.6 (±6.1) in the control group). Otherwise, we found no difference in the number of SLE-related outcomes such as renal biopsy or dialysis for AKI. Similarly, we found no difference in unspecific outcomes such as Characteristics of a matched SLE population admitted to French hospitals without any evidence of COVID-19 during the same period are also presented for information. *SAPS II is only available for ICU-admitted patients. †Standardised differences are given for significance of the difference between the first two groups. ‡Matching variables. AKI, acute kidney injury; AOF, associated organ failure; ICU, intensive care unit; Q1, first quartile; Q3, third quartile; SAPS II, Simplified Acute Physiology Score; SLE, systemic lupus erythematosus.

Survival at D90 of patients with SLE experiencing COVID-19-AOF in France (in red) from March 2020 to November 2020 compared with a matched control population (in blue) with COVID-19-AOF but without SLE admitted during the same period. For information, survival of a matched SLE population admitted in France during the same period without any evidence of COVID-19 is shown in green. P value is given for the time period D0-D30 for comparison between SLE patients with COVID-19-AOF and non-SLE patients with COVID-19-AOF. AOF, associated organ failure; D, day; SLE, systemic lupus erythematosus.

number of hospital stays, diagnosis of pulmonary embolism or coronary angiography for myocardial infarction.

Our analysis of the French national medical and administrative database showed that SLE is associated with a worsened prognosis during COVID-19-AOF requiring hospitalisation. Importantly, we observed an increased late-onset mortality, between D30 and D90, for hospitalised patients with SLE still alive 30 days after the first day of admission, independently of age, gender and various comorbidities such as chronic kidney disease.

Conversely, in our selected unmatched population, the crude analysis of the COVID-19-AOF outcome showed that hospitalised patients with SLE have an unchanged prognosis as compared with the general population. Such observation may be biased because patients with SLE are younger and more frequently female. On the other hand, patients with SLE have more comorbidities. 16 Using a matching strategy that was devised to limit such biases, a specific delayed risk was unravelled in hospitalised SLE patients with COVID-19-AOF. Such increased risk might be related to the high coinfection rate during or after COVID-19 in these patients. Patients with SLE could be more susceptible to coinfection due to their treatment. They may also be at risk of COVID-19-induced immune paralysis. Of note, SLE flares or cardiovascular events rates did not seem to be increased after COVID-19-AOF. Since we did not have access to patients' detailed files and treatments, we were not able to confirm that SLE disease went uneventful.

Several studies have assessed the specific prognosis of patients with SLE during COVID-19 and displayed heterogenous results. 8 9 17-20 Most studies analysed a mixed subset with various rheumatic diseases and included a very limited number of patients with SLE. Moreover, no matching strategy was used to limit the bias related to age, sex and comorbidities among the SLE population.

We found a relatively low number of patients with SLE among the French population with COVID-19-AOF (196 of 113 371, 0.2%) between March and November 2020, whereas Cordtz et al 21 recently reported an increased risk of hospitalisation for SLE patients with COVID-19 in Denmark compared with the general population. It might be due to a lack of precision in coding SLE procedures; however, our results fit well with the prevalence of SLE in France, estimated at 5 for 10 000. 22 Moreover, the characteristics of our patients with SLE are consistent with previously published large epidemiological studies on patients with SLE conducted in France. 22 Because it is a hospital database, we only had access to in-hospital mortality. Since patients with SLE are more likely to be admitted to hospital, the proportion of in-hospital mortality for patients with SLE is expected to be higher than for the general population. However, we found that most of the patients discharged before D90 went home; therefore, we can assume that a very limited number of them died after discharge. Follow-up was limited to 90 days after COVID-19, with data gathered before November 2020; thus, the investigated population encountered almost exclusively the original 'Wuhan' SARS-CoV-2 strain. 

Our work has several strengths. First, in accordance with the French Health Insurance System, PMSI gather exhaustive data of all French hospitals, meaning that our data included every patient with at least one diagnosis of SLE reported from 2011 to 2020. Thanks to linking between the successive hospitalisation episodes, we were able to examine all hospital records of each individual patient and to assess 30-day and 90-day outcomes. Our matched study allowed us to take into account several confounding factors that usually blur the comparison between patients with SLE and the general population. Although the severity of COVID-19-AOF was not included in the matching procedure, we observed a very similar rate of ICU admission, Simplified Acute Physiology Score II and healthcare use between patients with SLE and the matched control population, confirming the validity of the matching process.

COVID-19-AOF has a late-onset poor prognosis in patients with SLE. Further studies are warranted to delineate the clinical course of patients with SLE who survived severe COVID-19.

Systemic lupus erythematosus. The Lancet

Dexamethasone in hospitalized patients with Covid-19

In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Association between anti-interferon-alpha autoantibodies and COVID-19 in systemic lupus erythematosus

Type I interferon in the pathogenesis of lupus

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

SARS-CoV-2 infection among inpatients with systemic lupus erythematosus in France: a nationwide epidemiological study

COVID-19 in systemic lupus erythematosus: data from a survey on 417 patients

COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease

Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine

Challenges in assessing the burden of sepsis and understanding the inequalities of sepsis outcomes between National health systems: secular trends in sepsis and infection incidence and mortality in Germany

Sepsis and septic shock in France: incidences, outcomes and costs of care

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

The robust inference for the COX proportional hazards model

The burden of chronic kidney disease in systemic lupus erythematosus: a nationwide epidemiologic study

Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot

Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients

Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseases

Impact of first wave of SARS-CoV-2 infection in patients with systemic lupus erythematosus: weighting the risk of infection and flare

Incidence of COVID-19 hospitalisation in patients with systemic lupus erythematosus: a nationwide cohort study from Denmark

Prevalence and incidence of systemic lupus erythematosus in France: a 2010 nation-wide population-based study

The authors thank Celine Feger, MD (EMIBiotech) for her editorial support.

Funding PhD fellowship support for AM was provided by Agence Nationale pour la recherche (n°ANR-19-CE17-0029).Competing interests None declared.

Ethics approval In accordance with the French regulatory system regarding personal and medical data and after agreement of the institutional review board (IRB), our institution was allowed to access the PMSI database. We only had access to patients diagnosed with infection-associated organ failure and/or SLE according to our definition. All data were anonymised. This study does not involve human participants.Provenance and peer review Not commissioned; externally peer reviewed.Data availability statement Data are available upon reasonable request.Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

Arthur Mageau http:// orcid. org/ 0000-0002-2995-767X Karim Sacre http:// orcid. org/ 0000-0002-6544-234X